336 related articles for article (PubMed ID: 23470192)
1. Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs).
Duintjer Tebbens RJ; Pallansch MA; Kim JH; Burns CC; Kew OM; Oberste MS; Diop OM; Wassilak SG; Cochi SL; Thompson KM
Risk Anal; 2013 Apr; 33(4):680-702. PubMed ID: 23470192
[TBL] [Abstract][Full Text] [Related]
2. Modeling the dynamics of oral poliovirus vaccine cessation.
Thompson KM; Duintjer Tebbens RJ
J Infect Dis; 2014 Nov; 210 Suppl 1():S475-84. PubMed ID: 25316870
[TBL] [Abstract][Full Text] [Related]
3. Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation.
Duintjer Tebbens RJ; Thompson KM
J Infect Dis; 2014 Nov; 210 Suppl 1():S485-97. PubMed ID: 25316871
[TBL] [Abstract][Full Text] [Related]
4. Update on Vaccine-Derived Polioviruses - Worldwide, January 2014-March 2015.
Diop OM; Burns CC; Sutter RW; Wassilak SG; Kew OM;
MMWR Morb Mortal Wkly Rep; 2015 Jun; 64(23):640-6. PubMed ID: 26086635
[TBL] [Abstract][Full Text] [Related]
5. Sabin Vaccine Reversion in the Field: a Comprehensive Analysis of Sabin-Like Poliovirus Isolates in Nigeria.
Famulare M; Chang S; Iber J; Zhao K; Adeniji JA; Bukbuk D; Baba M; Behrend M; Burns CC; Oberste MS
J Virol; 2016 Jan; 90(1):317-31. PubMed ID: 26468545
[TBL] [Abstract][Full Text] [Related]
6. Update on vaccine-derived polioviruses--worldwide, July 2009-March 2011.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2011 Jul; 60(25):846-50. PubMed ID: 21716199
[TBL] [Abstract][Full Text] [Related]
7. Circulating vaccine-derived polioviruses: current state of knowledge.
Kew OM; Wright PF; Agol VI; Delpeyroux F; Shimizu H; Nathanson N; Pallansch MA
Bull World Health Organ; 2004 Jan; 82(1):16-23. PubMed ID: 15106296
[TBL] [Abstract][Full Text] [Related]
8. Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine - Worldwide, 2016.
Hampton LM; Farrell M; Ramirez-Gonzalez A; Menning L; Shendale S; Lewis I; Rubin J; Garon J; Harris J; Hyde T; Wassilak S; Patel M; Nandy R; Chang-Blanc D;
MMWR Morb Mortal Wkly Rep; 2016 Sep; 65(35):934-8. PubMed ID: 27606675
[TBL] [Abstract][Full Text] [Related]
9. Eradicating polio: how the world's pediatricians can help stop this crippling illness forever.
Orenstein WA;
Pediatrics; 2015 Jan; 135(1):196-202. PubMed ID: 25548328
[TBL] [Abstract][Full Text] [Related]
10. Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes.
Thompson KM; Duintjer Tebbens RJ
BMC Infect Dis; 2015 Sep; 15():374. PubMed ID: 26381878
[TBL] [Abstract][Full Text] [Related]
11. Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses.
Duintjer Tebbens RJ; Pallansch MA; Kalkowska DA; Wassilak SG; Cochi SL; Thompson KM
Risk Anal; 2013 Apr; 33(4):703-49. PubMed ID: 23521018
[TBL] [Abstract][Full Text] [Related]
12. Modeling strategies to increase population immunity and prevent poliovirus transmission in the high-risk area of northwest Nigeria.
Kalkowska DA; Duintjer Tebbens RJ; Thompson KM
J Infect Dis; 2014 Nov; 210 Suppl 1():S412-23. PubMed ID: 25316863
[TBL] [Abstract][Full Text] [Related]
13. A developing country perspective on vaccine-associated paralytic poliomyelitis.
John TJ
Bull World Health Organ; 2004 Jan; 82(1):53-7; discussion 57-8. PubMed ID: 15106301
[TBL] [Abstract][Full Text] [Related]
14. Transmission dynamics of oral polio vaccine viruses and vaccine-derived polioviruses on networks.
Kim JH; Rho SH
J Theor Biol; 2015 Jan; 364():266-74. PubMed ID: 25264265
[TBL] [Abstract][Full Text] [Related]
15. Molecular evolution of oral poliovirus vaccine strains during multiplication in humans and possible implications for global eradication of poliovirus.
Friedrich F
Acta Virol; 2000 Apr; 44(2):109-17. PubMed ID: 10989702
[TBL] [Abstract][Full Text] [Related]
16. Assessing the stability of polio eradication after the withdrawal of oral polio vaccine.
Famulare M; Selinger C; McCarthy KA; Eckhoff PA; Chabot-Couture G
PLoS Biol; 2018 Apr; 16(4):e2002468. PubMed ID: 29702638
[TBL] [Abstract][Full Text] [Related]
17. Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs.
Duintjer Tebbens RJ; Thompson KM
BMC Infect Dis; 2015 Sep; 15():390. PubMed ID: 26404780
[TBL] [Abstract][Full Text] [Related]
18. Update on Vaccine-Derived Poliovirus Outbreaks - Worldwide, January 2018-June 2019.
Jorba J; Diop OM; Iber J; Henderson E; Zhao K; Quddus A; Sutter R; Vertefeuille JF; Wenger J; Wassilak SGF; Pallansch MA; Burns CC
MMWR Morb Mortal Wkly Rep; 2019 Nov; 68(45):1024-1028. PubMed ID: 31725706
[TBL] [Abstract][Full Text] [Related]
19. Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis.
Ciapponi A; Bardach A; Rey Ares L; Glujovsky D; Cafferata ML; Cesaroni S; Bhatti A
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011260. PubMed ID: 31801180
[TBL] [Abstract][Full Text] [Related]
20. Introduction of Inactivated Poliovirus Vaccine and Switch from Trivalent to Bivalent Oral Poliovirus Vaccine - Worldwide, 2013-2016.
Immunization Systems Management Group of the Global Polio Eradication Initiative
MMWR Morb Mortal Wkly Rep; 2015 Jul; 64(25):699-702. PubMed ID: 26135591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
